BRIDGEBIO PHARMA INC (BBIO)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About BRIDGEBIO PHARMA INC
BridgeBio Pharma, Inc. is a NASDAQ-listed biotechnology company that develops medicines for genetic diseases, cancer-related conditions, and gene therapy applications. In FY2025, it generated $502.1 million of revenue. Founded in 2015 and based in Palo Alto, California, BridgeBio builds its business around a broad clinical pipeline and partnered research base.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
BRIDGEBIO PHARMA INC's Technical Indicators Summary
BBIO shows a robust trend backdrop with ADX above 30 and the price trading well above short, medium and 200-day averages, supporting the strong-buy assessment. Momentum is positive and RSI is mildly elevated but not extreme, while MACD is modest, pointing to steady internals. On-balance volume confirms buying pressure and ATR points to moderate volatility; the classic pivot sits slightly above the market and could act as near-term resistance. Technical takeaway: Strong Buy — strong trend and broad moving-average support are the primary technical supports.
| Indicator | Value |
|---|---|
RSI (14) | 60.91 |
Stochastic %K (14, 3, 3) | 60.13 |
CCI (20) | 67.37 |
WPR (14) | -43.34 |
Momentum (10) | 1.33 |
MFI | 61.94 |
MACD Level (12, 26) | 1.75 |
Bollinger Bands | $79.41 - $86.04 |
ATR (14) | $3.03 (3.57%) |
ADX (14) | 31.38 |
OBV | 41,601,457 |
Classic Pivot Point | $85.51 |
Fibonacci Pivot Point | $85.51 |
Exponential Moving Averages | $70.65 - $83.41(5 indicators) |
Simple Moving Averages | $72.50 - $82.72(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A small early pop has BBIO 0.60% over yesterday’s close of 83.70. The peer group is marking time, with sector returns hovering at 0.25%. BBIO price target lifted to 111 by JP Morgan, signaling renewed upside.
Trading Volume
Below 10d avg (2.0M)
652.8K
vs S&P 500 Today
Moderate Outperformance
+0.35%
52-Week Position
Upper range
80.2%
Updated: August 12, 2026 at 17:13 UTC